

Applicants : Ron S. Israeli, et al.
Serial No. : 10/614,625
Filed : July 2, 2003
Page 2

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-23. (Canceled)

24. (Previously Presented) A method comprising administering an inhibitor of the neurocarboxypeptidase activity of prostate specific membrane antigen so as to inhibit release of glutamate by N-acetylaspartylglutamic acid (NAAG) hydrolysis.

25. (Previously Presented) The method of claim 24, wherein the inhibitor is MTXglu₃, pteglu₅ or pABAglu₅.

26. (New) A pharmaceutical composition comprising:
(i) a therapeutically effective amount of a NAALADase inhibitor, and
(ii) a pharmaceutically acceptable carrier.

27. (New) The pharmaceutical composition of claim 26, wherein the effective amount is 30-10,000 mg/m².

28. (New) The pharmaceutical composition of claim 26, wherein the effective amount is 100-10,000 mg/m².

29. (New) The pharmaceutical composition of claim 26, wherein the effective amount is 300-1000 mg/m².

Applicants : Ron S. Israeli, et al.
Serial No. : 10/614,625
Filed : July 2, 2003
Page 3

30. (New) A pharmaceutical composition comprising:
 - (i) an effective amount of a NAALADase inhibitor to treat cancer, and
 - (ii) a pharmaceutically acceptable carrier.
31. (New) The pharmaceutical composition of claim 30, wherein the cancer is prostate cancer.
32. (New) The pharmaceutical composition of claim 30, wherein the cancer is kidney, colon or bladder cancer.
33. (New) A pharmaceutical composition as in claims 30, 31, or 32, further comprising at least one additional therapeutic agent.
34. (New) The pharmaceutical composition of claim 33, wherein the therapeutic agent is a hormone, growth factor or cytokine.
35. (New) The pharmaceutical composition of claim 30, wherein the NAALADase inhibitor is a cytotoxic agent, enzyme or immunomodulator.